Recent advances in molecular diagnosis of thyroid cancer

Journal of Thyroid Research

Volumn 2011, Issue , 2011, Pages

  Legakis, Ioannis ^a   Syrigos, Konstantinos ^b  

^a HENRY DUNANT HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN RET; RADIOACTIVE IODINE; SORAFENIB; TRANSCRIPTION FACTOR PAX8; VANDETANIB;

ADVANCED CANCER; BRAF GENE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CARCINOGENESIS; CHROMOSOME REARRANGEMENT; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; DNA DAMAGE; DNA METHYLATION; EPIGENETICS; GENE FUNCTION; GENE INACTIVATION; GENE MUTATION; GENETIC DISORDER; GENETIC REGULATION; HUMAN; MOLECULAR DIAGNOSIS; NONHUMAN; ONCOGENE RAS; PAX8 GENE; PPARGAMMA GENE; PRIORITY JOURNAL; RET GENE; REVIEW; SIGNAL TRANSDUCTION; THYROID CANCER; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID NODULE; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

EID: 84865381348     PISSN: 20908067     EISSN: 20420072     Source Type: Journal    
DOI: 10.4061/2011/384213     Document Type: Review

References (114)

1. L. Leenhardt, P. Grosclaude, and L. Cherie-Challine, "Increased incidence of thyroid carcinoma in france: a true epidemic or thyroid nodule management effects? Report from the french thyroid cancer committee", Thyroid, vol. 14, no. 12, pp. 1056-1060, 2004. (Pubitemid 40076130)
2. L. Davies and H. G. Welch, "Increasing incidence of thyroid cancer in the United States, 1973-2002", Journal of the American Medical Association, vol. 295, no. 18, pp. 2164-2167, 2006.
3. L. Ries, D. Melbert, M. Krapcho et al., Eds., SEER Cancer Statistics Review, 1975-2004, National Cancer Institute, Bethesda. Md, USA, 2007.
4. S. A. Hundahl, I. D. Fleming, A. M. Fremgen, and H. R. Menck, "A National Cancer Data Base report on 53, 856 cases of thyroid carcinoma treated in the U. S., 1985-1995", Cancer, vol. 83, no. 12, pp. 2638-2648, 1998. (Pubitemid 29019586)
5. Y. S. Swamy Venkatesh, N. G. Ordonez, P. N. Schultz, R. C. Hickey, H. Goepfert, and N. A. Samaan, "Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases", Cancer, vol. 66, no. 2, pp. 321-330, 1990. (Pubitemid 20205915)
6. M. L. Carcangiu, T. Steeper, G. Zampi, and J. Rosai, "Anaplastic thyroid carcinoma: a study of 70 cases", American Journal of Clinical Pathology, vol. 83, no. 2, pp. 135-158, 1985. (Pubitemid 15128839)
7. Y. E. Nikiforov, "Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas", Endocrine Pathology, vol. 15, no. 4, pp. 319-327, 2004. (Pubitemid 40208912)
8. J. Rosai, E. A. Saxen, and L. Woolner, "Session III: undifferentiated and poorly differentiated carcinoma", Seminars in Diagnostic Pathology, vol. 2, no. 2, pp. 123-136, 1985. (Pubitemid 15085902)
9. K. J. Harrington, V. J. Michalaki, L. Vini et al., "Management of non-Hodgkin's lymphoma of the thyroid: the Royal Marsden Hospital experience", British Journal of Radiology, vol. 78, no. 929, pp. 405-410, 2005. (Pubitemid 40691742)
10. M. R. Castro and H. Gharib, "Thyroid nodules and cancer", Postgraduate Medicine, vol. 107, no. 1, pp. 113-124, 2000. (Pubitemid 30048811)
11. H. Gharib, J. R. Goellner, and A. R. Zinsmeister, "Fine-needle aspiration biopsy of the thyroid. The problem of suspicious cytologic findings", Annals of Internal Medicine, vol. 101, no. 1, pp. 25-28, 1984. (Pubitemid 14088062)
12. G. M. Sclabas, G. A. Staerkel, S. E. Shapiro et al., "Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients", American Journal of Surgery, vol. 186, no. 6, pp. 702-710, 2003. (Pubitemid 37522110)
13. M. J. Schlumberger, "Papillary and follicular thyroid carcinoma", The New Engl and Journal of Medicine, vol. 338, no. 5, pp. 297-306, 1998. (Pubitemid 28065257)
14. J. Jonklaas, N. J. Sarlis, D. Litofsky et al., "Outcomes of patients with differentiated thyroid carcinoma following initial therapy", Thyroid, vol. 16, no. 12, pp. 1229-1242, 2006. (Pubitemid 46080167)
15. I. Legakis, K. Koutsoupa, K. Dafermou, I. Katsafados, S. P. Bakas, and E. Lakka-Papadodima, "Radioiodine treatment using RH-TSH in patients with well-differentiated thyroid cancer", in European Thyroid Association Annual Meeting, Edinburgh, UK, abstract #P-180, 2003.
16. H. G. Suarez, "Genetic alterations in human epithelial thyroid tumours", Clinical Endocrinology, vol. 48, no. 5, pp. 531-546, 1998. (Pubitemid 28252989)
17. G. M. Venkataraman, M. Yatin, R. Marcinek, and K. B. Ain, "Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I symporter gene methylation status", Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 7, pp. 2449-2457, 1999.
18. M. A. Savelonas, D. K. Iakovidis, I. Legakis, and D. Maroulis, "Active contours guided by echogenicity and texture for delineation of thyroid nodules in ultrasound images", IEEE Transactions on Information Technology in Biomedicine, vol. 13, no. 4, pp. 519-527, 2009.
19. I. Legakis, M. A. Savelonas, D. Maroulis, and D. K. Iakovidis, "Computer-based nodule malignancy risk assessment in thyroid ultrasound images", International Journal of Computers and Applications. In press.
20. D. S. Cooper, G. M. Doherty, B. R. Haugen et al., "Management guidelines for patients with thyroid nodules and differentiated thyroid cancer", Thyroid, vol. 16, no. 2, pp. 109-141, 2006.
21. K. Koutsoupa, I. Legakis, K. Dafermou et al., "RH-TSH stimulated TG as a marker of disease activity in patients with well differentiated thyroid cancer", in European Thyroid Association Annual Meeting, Edinburgh, UK, abstract #P-181, 2003.
22. R. M. Tuttle, "Risk-adapted management of thyroid cancer", Endocrine Practice, vol. 14, no. 6, pp. 764-774, 2008.
23. R. J. Robbins and S. M. Larson, "The value of positron emission tomography (PET) in the management of patients with thyroid cancer", Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 22, no. 6, pp. 1047-1059, 2008.
24. S. I. Sherman, "Early clinical studies of novel therapies for thyroid cancers", Endocrinology and Metabolism Clinics of North America, vol. 37, no. 2, pp. 511-524, 2008. (Pubitemid 351698088)
25. A. Fusco, M. Grieco, and M. Santoro, "A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases", Nature, vol. 328, no. 6126, pp. 170-172, 1987. (Pubitemid 17108219)
26. G. Viglietto, G. Chiappetta, F. J. Martinez-Tello et al., "RET/PTC oncogene activation is an early event in thyroid carcinogenesis", Oncogene, vol. 11, no. 6, pp. 1207-1210, 1995.
27. M. N. Nikiforova, J. R. Stringer, R. Blough, M. Medvedovic, J. A. Fagin, and Y. E. Nikiforov, "Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells", Science, vol. 290, no. 5489, pp. 138-141, 2000.
28. E. Roccato, P. Bressan, G. Sabatella et al., "Proximity of TPR and NTRK1 rearranging loci in human thyrocytes", Cancer Research, vol. 65, no. 7, pp. 2572-2576, 2005. (Pubitemid 40490053)
29. M. Santoro, F. Carlomagno, I. D. Hay et al., "Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype", Journal of Clinical Investigation, vol. 89, no. 5, pp. 1517-1522, 1992.
30. M. Santoro, N. Sabino, Y. Ishizaka et al., "Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours", British Journal of Cancer, vol. 68, no. 3, pp. 460-464, 1993. (Pubitemid 23258446)
31. M. Santoro, G. A. Thomas, G. Vecchio et al., "Gene rearrangement and Chernobyl related thyroid cancers", British Journal of Cancer, vol. 82, no. 2, pp. 315-322, 2000. (Pubitemid 30045376)
32. G. Vecchio and M. Santoro, "Oncogenes and thyroid cancer", Clinical Chemistry and Laboratory Medicine, vol. 38, no. 2, pp. 113-116, 2000. (Pubitemid 30245778)
33. F. Moretti, S. Nanni, and A. Pontecorvi, "Molecular pathogenesis of thyroid nodules and cancer", Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 14, no. 4, pp. 517-539, 2000. (Pubitemid 32293853)
34. D. L. Learoyd, M. Messina, J. Zedenius, A. I. Guinea, L. W. Delbridge, and B. G. Robinson, "RET/PTC and RET tyrosine kinase expression in adult papillary thyroid carcinomas", Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 10, pp. 3631-3635, 1998. (Pubitemid 28500901)
35. Q. De Vita, M. Zannini, A. M. Cirafici et al., "Expression of the RET/PTC1 oncogene impairs the activity of TTF-1 and Pax-8 thyroid transcription factors", Cell Growth and Differentiation, vol. 9, no. 1, pp. 97-103, 1998. (Pubitemid 28049532)
36. M. Santoro, R. M. Melillo, and A. Fusco, "RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology prize lecture", European Journal of Endocrinology, vol. 155, no. 5, pp. 645-653, 2006. (Pubitemid 44857487)
37. D. J. Powell, J. Russell, K. I. Nibu et al., "The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids", Cancer Research, vol. 58, no. 23, pp. 5523-5528, 1998. (Pubitemid 28551140)
38. J. Y. Cho, J. E. Sagartz, C. C. Capen, E. L. Mazzaferri, and S. M. Jhiang, "Early cellular abnormalities induced by RET/PTC1 oncogene in thyroid-targeted transgenic mice", Oncogene, vol. 18, no. 24, pp. 3659-3665, 1999. (Pubitemid 29322392)
39. M. Sobrinho-Simoes, V. Máximo, A. S. Rocha et al., "Intragenic mutations in thyroid cancer", Endocrinology and Metabolism Clinics of North America, vol. 37, no. 2, pp. 333-362, 2008. (Pubitemid 351698087)
40. Y. E. Nikiforov, D. L. Steward, T. M. Robinson-Smith et al., "Molecular testing for mutations in improving the fineneedle aspiration diagnosis of thyroid nodules", Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 6, pp. 2092-2098, 2009.
41. Y. E. Nikiforov, "RET/PTC rearrangement in thyroid tumors", Endocrine Pathology, vol. 13, no. 1, pp. 3-16, 2002. (Pubitemid 34665111)
42. G. Tallini and S. L. Asa, "RET oncogene activation in papillary thyroid carcinoma", Advances in Anatomic Pathology, vol. 8, no. 6, pp. 345-354, 2001.
43. O. M. Sheils, J. J. O'Leary, V. Uhlmann, K. Luttich, and E. C. Sweeney, "ret/PTC-1 activation in Hashimoto thyroiditis", International Journal of Surgical Pathology, vol. 8, no. 3, pp. 185-189, 2000.
44. R. Elisei, C. Romei, T. Vorontsova et al., "RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults", Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 7, pp. 3211-3216, 2001. (Pubitemid 32673490)
45. C. C. Cheung, B. Carydis, S. Ezzat, Y. C. Bedard, and S. L. Asa, "Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer", Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 5, pp. 2187-2190, 2001. (Pubitemid 32472938)
46. G. Tallini, M. Santoro, M. Helie et al., "RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes", Clinical Cancer Research, vol. 4, no. 2, pp. 287-294, 1998. (Pubitemid 28122740)
47. M. Santoro, M. Papotti, G. Chiappetta et al., "RET activation and clinicopathologic features in poorly differentiated thyroid tumors", Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 1, pp. 370-379, 2002. (Pubitemid 34084717)
48. C. Lanzi, G. Cassinelli, T. Pensa et al., "Inhibition of transforming activity of the ret/ptc1 oncoprotein by a 2-indolinone derivative", International Journal of Cancer, vol. 85, no. 3, pp. 384-390, 2000. (Pubitemid 30030413)
49. V. Gupta-Abramson, A. B. Troxel, A. Nellore et al., "Phase II trial of sorafenib in advanced thyroid cancer", Journal of Clinical Oncology, vol. 26, no. 29, pp. 4714-4719, 2008.
50. R. T. Kloos, M. D. Ringel, M. V. Knopp et al., "Phase II trial of sorafenib in metastatic thyroid cancer", Journal of Clinical Oncology, vol. 27, no. 10, pp. 1675-1684, 2009.
51. S. I. Sherman, "Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers", Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 5, pp. 1493-1499, 2009.
52. J. A. Fagin, K. Matsuo, A. Karmakar, D. L. Chen, S. H. Tang, and H. P. Koeffler, "High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas", Journal of Clinical Investigation, vol. 91, no. 1, pp. 179-184, 1993. (Pubitemid 23037270)
53. M. Barbacid, "ras genes", Annual Review of Biochemistry, vol. 56, pp. 779-827, 1987.
54. R. E. Finney and J. M. Bishop, "Predisposition to neoplastic transformation caused by gene replacement of H-ras1", Science, vol. 260, no. 5113, pp. 1524-1527, 1993. (Pubitemid 23273271)
55. J. L. Meinkoth, "Biology of Ras in thyroid cells", Cancer Treatment and Research, vol. 122, pp. 131-148, 2004.
56. V. Vasko, M. Ferrand, J. Di Cristofaro, P. Carayon, J. F. Henry, and C. De Micco, "Specific pattern of RAS oncogene mutations in follicular thyroid tumors", Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 6, pp. 2745-2752, 2003. (Pubitemid 36724451)
57. H. Namba, S. A. Rubin, and J. A. Fagin, "Point mutations of ras oncogenes are an early event in thyroid tumorigenesis", Molecular Endocrinology, vol. 4, no. 10, pp. 1474-1479, 1990. (Pubitemid 20356608)
58. F. Basolo, F. Pisaturo, L. E. Pollina et al., "N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression", Thyroid, vol. 10, no. 1, pp. 19-23, 2000. (Pubitemid 30090361)
59. C. T. Esapa, S. J. Johnson, P. Kendall-Taylor, T. W. Lennard, and P. E. Harris, "Prevalence of Ras mutations in thyroid neoplasia", Clin Endocrinol, vol. 50, no. 4, pp. 529-535, 1999. (Pubitemid 29193238)
60. N. Motoi, A. Sakamoto, T. Yamochi, H. Horiuchi, T. Motoi, and R. Machinami, "Role of ras mutation in the progression of thyroid carcinoma offollicular epithelial origin", Pathology Research and Practice, vol. 196, no. 1, pp. 1-7, 2000. (Pubitemid 30046520)
61. P. Rochefort, B. Caillou, F. M. Michiels et al., "Thyroid pathologies in transgenic mice expressing a human activated Ras gene driven by a thyroglobulin promoter", Oncogene, vol. 12, no. 1, pp. 111-118, 1996. (Pubitemid 26041246)
62. G. Garcia-Rostan, H. Zhao, R. L. Camp et al., "Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer", Journal of Clinical Oncology, vol. 21, no. 17, pp. 3226-3235, 2003. (Pubitemid 46606254)
63. R. Ciampi and Y. E. Nikiforov, "Minireview: RET/PTC rearrangements and braf mutations in thyroid tumorigenesis", Endocrinology, vol. 148, no. 3, pp. 936-941, 2007.
64. H. Davies, G. R. Bignell, C. Cox et al., "Mutations of the BRAF gene in human cancer", Nature, vol. 417, no. 6892, pp. 949-954, 2002. (Pubitemid 34716871)
65. K. E. Mercer and C. A. Pritchard, "Raf proteins and cancer: B-Raf is identified as a mutational target", Biochimica et Biophysica Acta, vol. 1653, no. 1, pp. 25-40, 2003. (Pubitemid 36627818)
66. M. J. Garnett and R. Marais, "Guilty as charged: B-RAF is a human oncogene", Cancer Cell, vol. 6, no. 4, pp. 313-319, 2004. (Pubitemid 39361432)
67. V. Vasko, M. Ferrand, J. Di Cristofaro, P. Carayon, J. F. Henry, and C. De Micco, "Specific pattern of RAS oncogene mutations in follicular thyroid tumors", Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 6, pp. 2745-2752, 2003. (Pubitemid 36724451)
68. M. Xing, "BRAF mutation in thyroid cancer", Endocrine-Related Cancer, vol. 12, no. 2, pp. 245-262, 2005. (Pubitemid 40896444)
69. M. Xing, "BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications", Endocrine Reviews, vol. 28, no. 7, pp. 742-762, 2007. (Pubitemid 350294294)
70. V. Trovisco, I. V. de Castro, P. Soares et al., "BRAF mutations are associated with some histological types of papillary thyroid carcinoma", Journal of Pathology, vol. 202, no. 2, pp. 247-251, 2004. (Pubitemid 38208663)
71. R. Ciampi, J. A. Knauf, R. Kerler et al., "Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer", Journal of Clinical Investigation, vol. 115, no. 1, pp. 94-101, 2005. (Pubitemid 40385509)
72. G. Oler, K. N. Ebina, P. Michaluart, E. T. Kimura, and J. Cerutti, "Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis", Clinical Endocrinology, vol. 62, no. 4, pp. 509-511, 2005.
73. P. Hou, D. Liu, and M. M. Xing, "Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer", Cell Cycle, vol. 6, no. 3, pp. 377-379, 2007.
74. S. Moretti, A. Macchiarulo, V. De Falco et al., "Biochemical and molecular characterization of the novel BRAF (V599Ins) mutation detected in a classic papillary thyroid carcinoma", Oncogene, vol. 25, no. 30, pp. 4235-4240, 2006. (Pubitemid 44079457)
75. M. Xing, "The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer", Clinical Endocrinology, vol. 63, no. 3, pp. 263-266, 2005. (Pubitemid 41233442)
76. P. Hou and M. Xing, "Absence of germline mutations in genes within the MAP kinase pathway in familial non-medullary thyroid cancer", Cell Cycle, vol. 5, no. 17, pp. 2036-2039, 2006. (Pubitemid 44435312)
77. J. A. Knauf, X. Ma, E. P. Smith et al., "Targeted expression of BRAF in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation", Cancer Research, vol. 65, no. 10, pp. 4238-4245, 2005. (Pubitemid 40775662)
78. D. Liu, Z. Liu, S. Condouris, and M. M. Xing, "BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells", Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 6, pp. 2264-2271, 2007. (Pubitemid 46997132)
79. D. Liu, Z. Liu, D. Jiang, A. P. Dackiw, and M. M. Xing, "Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations", Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 12, pp. 4686-4695, 2007. (Pubitemid 350223445)
80. M. Xing, W. H. Westra, R. P. Tufano et al., "BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer", Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 12, pp. 6373-6379, 2005. (Pubitemid 41759286)
81. C. Durante, E. Puxeddu, E. Ferretti et al., "Brief report: BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism", Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 7, pp. 2840-2843, 2007. (Pubitemid 47037399)
82. C. Romei, R. Ciampi, P. Faviana et al., "BRAF mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer", Endocrine-Related Cancer, vol. 15, no. 2, pp. 511-520, 2008. (Pubitemid 351880839)
83. T. J. Giordano, R. Kuick, D. G. Thomas et al., "Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis", Oncogene, vol. 24, no. 44, pp. 6646-6656, 2005. (Pubitemid 41486795)
84. J. Di Cristofaro, M. Silvy, A. Lanteaume, M. Marcy, P. Carayon, and C. De Micco, "Expression of tpo mRNA in thyroid tumors: quantitiative PCR analysis and correlation with alterations of ret, Braf, ras and pax8 genes", Endocrine-Related Cancer, vol. 13, no. 2, pp. 485-495, 2006. (Pubitemid 43886671)
85. C. Mian, S. Barollo, G. Pennelli et al., "Molecular characteristics in papillary thyroid cancers (PTCs) with no I uptake", Clinical Endocrinology, vol. 68, no. 1, pp. 108-116, 2008. (Pubitemid 350243490)
86. I. Vivanco and C. L. Sawyers, "The phosphatidylinositol 3-kinase-AKT pathway in human cancer", Nature Reviews Cancer, vol. 2, no. 7, pp. 489-501, 2002. (Pubitemid 37328931)
87. J. A. Fresno Vara, E. Casado, J. de Castro, P. Cejas, C. Belda-Iniesta, and M. Gonzalez-Baron, "P13K/Akt signalling pathway and cancer", Cancer Treatment Reviews, vol. 30, no. 2, pp. 193-204, 2004. (Pubitemid 38418057)
88. I. Sansal and W. R. Sellers, "The biology and clinical relevance of the PTEN tumor suppressor pathway", Journal of Clinical Oncology, vol. 22, no. 14, pp. 2954-2963, 2004. (Pubitemid 41079915)
89. G. García-Rostan, A. M. Costa, I. Pereira-Castro et al., "Mutation of the PIK3CA gene in anaplastic thyroid cancer", Cancer Research, vol. 65, no. 22, pp. 10199-10207, 2005. (Pubitemid 41743711)
90. G. Wu, E. Mambo, Z. Guo et al., "Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors", Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 8, pp. 4688-4693, 2005. (Pubitemid 41159359)
91. P. Hou, D. Liu, Y. Shan et al., "Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer", Clinical Cancer Research, vol. 13, no. 4, pp. 1161-1170, 2007. (Pubitemid 46424056)
92. Y. Wang, P. Hou, H. Yu et al., "High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/Akt pathway in thyroid tumors", Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 6, pp. 2387-2390, 2007. (Pubitemid 46997152)
93. G. Tallini, "Molecular pathobiology of thyroid neoplasms", Endocrine Pathology, vol. 13, no. 4, pp. 271-288, 2002. (Pubitemid 36237982)
94. T. G. Kroll, P. Sarraf, L. Pecciarini et al., "PAX8-PPARy1 fusion in oncogene human thyroid carcinoma", Science, vol. 289, no. 5483, pp. 1357-1360, 2000. (Pubitemid 30656054)
95. H. Ying, H. Suzuki, LI. Zhao, M. C. Willingham, P. Meltzer, and S. Y. Cheng, "Mutant thyroid hormone receptor j8 represses the expression and transcriptional activity of peroxisome proliferator-activated receptor y during thyroid carcinogenesis", Cancer Research, vol. 63, no. 17, pp. 5274-5280, 2003. (Pubitemid 37139841)
96. A. R. Marques, C. Espadinha, A. L. Catarino et al., "Expression of PAX8-PPARy1 rearrangements in both follicular thyroid carcinomas and adenomas", Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 8, pp. 3947-3952, 2002. (Pubitemid 34879553)
97. P. Castro, A. P. Rebocho, R. J. Soares et al., "PAX8-PPARy rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma", Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 1, pp. 213-220, 2006. (Pubitemid 43069140)
98. N. R. Farid, Y. Shi, and M. Zou, "Molecular basis of thyroid cancer", Endocrine Reviews, vol. 15, no. 2, pp. 202-232, 1994. (Pubitemid 24129183)
99. D. L. Segev, C. Umbricht, and M. A. Zeiger, "Molecular pathogenesis of thyroid cancer", Surgical Oncology, vol. 12, no. 2, pp. 69-90, 2003. (Pubitemid 37289013)
100. R. Donghi, A. Longoni, S. Pilotti, P. Michieli, G. Della Porta, and M. A. Pierotti, "Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland", Journal of Clinical Investigation, vol. 91, no. 4, pp. 1753-1760, 1993. (Pubitemid 23127381)
101. Y. Dobashi, H. Sugimura, A. Sakamoto et al., "Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas", Diagnostic Molecular Pathology, vol. 3, no. 1, pp. 9-14, 1994. (Pubitemid 24064788)
102. T. Ito, T. Seyama, T. Mizuno et al., "Genetic alterations in thyroid tumor progression: association with p53 gene mutations", Japanese Journal of Cancer Research, vol. 84, no. 5, pp. 526-531, 1993. (Pubitemid 23193811)
103. Y. Takeuchi, T. Daa, K. Kashima, S. Yokoyama, I. Nakayama, and S. Noguchi, "Mutations of p53 in thyroid carcinoma with an insular component", Thyroid, vol. 9, no. 4, pp. 377-381, 1999. (Pubitemid 29206849)
104. X. Matias-Guiu, A. Villanueva, M. Cuatrecasas, G. Capella, A. De Leiva, and J. Prat, "p53 in a thyroid follicular carcinoma with foci of poorly differentiated and anaplastic carcinoma", Pathology Research and Practice, vol. 192, no. 12, pp. 1242-1249, 1996. (Pubitemid 127540795)
105. K. M. D. La Perle, S. M. Jhiang, and C. C. Capen, "Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas", American Journal of Pathology, vol. 157, no. 2, pp. 671-677, 2000. (Pubitemid 30626925)
106. D. J. Powell Jr., J. P. Russell, G. Li et al., "Altered gene expression in immunogenic poorly differentiated thyroid carcinomas from RET/PTC3p53-/-mice", Oncogene, vol. 20, no. 25, pp. 3235-3246, 2001. (Pubitemid 32553676)
107. F. Moretti, A. Farsetti, S. Soddu et al., "p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells", Oncogene, vol. 14, no. 6, pp. 729-740, 1997. (Pubitemid 27095865)
108. J. A. Fagin, S. H. Tang, K. Zeki, R. Di Lauro, A. Fusco, and R. Gonsky, "Reexpression of thyroid peroxidase in a derivative of an undifferentiated thyroid carcinoma cell line by introduction of wild-type p53", Cancer Research, vol. 56, no. 4, pp. 765-771, 1996. (Pubitemid 26055465)
109. P. A. Jones and S. B. Baylin, "The epigenomics of cancer", Cell, vol. 128, no. 4, pp. 683-692, 2007. (Pubitemid 46273572)
110. M. M. Xing, "Minireview: gene methylation in thyroid tumorigenesis", Endocrinology, vol. 148, no. 3, pp. 948-953, 2007.
111. T. Akagi, Q. T. Luong, D. Gui et al., "Induction of sodium iodide symporter gene and molecular characterisation of HNF3j8/FoxA2, TTF-1 and C/EBPj8 in thyroid carcinoma cells", British Journal of Cancer, vol. 99, no. 5, pp. 781-788, 2008.
112. G. Riesco-Eizaguirre and P. Santisteban, "New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy", Endocrine-Related Cancer, vol. 14, no. 4, pp. 957-977, 2007. (Pubitemid 351252429)
113. T. Kouzarides, "Chromatin modifications and their function", Cell, vol. 128, no. 4, pp. 693-705, 2007. (Pubitemid 46273577)
114. A. H. Ting, K. M. McGarvey, and S. B. Baylin, "The cancer epigenome-components and functional correlates", Genesand Development, vol. 20, no. 23, pp. 3215-3231, 2006.